Use of Low-frequency Magnetic Fields in the Hybrid Treatment of COVID-19 Patients

Summary

The purpose of this study was to evaluate the efficacy of low-frequency magnetic field in the hybrid treatment of COVID-19 patients, i.e., including magnetostimulation in the standard treatment. The authors evaluated among other things, the immunocorrective therapeutic effect of magnetostimulation, improving the defensive functions of the immune system and thus supporting the immune function by, among other things, suppressing the "cytokine storm".

After application of low-frequency magnetic field in the hybrid treatment of COVID-19 patients, the authors expected: a decrease in the level of proinflammatory factors (IL - 6), restoration of homeostasis in the body with regards to the range of parameters evaluated in laboratory tests (WBC, MONO, PLT, CRP, d-dimers) and normalization of the following parameters: arterial blood pressure, the number of breaths/min, saturation, temperature.

Conditions

• COVID-19
• COVID-19 Respiratory Infection
• COVID-19 Pneumonia

Interventions

OTHER

magnetostimulation

Treatment parameters: 12 minutes M2P2 program, with increasing intensity from 1 to 8. The authors applied magnetic field with a frequency of 180 - 190 Hz, pulse packet frequencies between 12.5 and 29 Hz, packet groups 2.8 - 7.6 Hz, series 0.08 - 0.3 Hz, with magnetic induction B= 3.2 µT (on average) and B = 40 µT at a pulse peak.

OTHER

standard therapy

Standard therapy used in all patients consisted of the use of pharmacological agents necessary to treat the viral infection (antiviral drugs, antibiotics, dexamethasone) and the inclusion of proper care, education, occupational therapy, self-service learning, breathing exercises and motor mobilization.

Sponsors & Collaborators

• Medical University of Lodz

  lead OTHER

Principal Investigators

• Marta Woldańska-Okońska, profesor · Department of Rehabilitation and Physical Medicine, Medical University of Lodz

• Agnieszka Jankowska, doctor · Department of Rehabilitation and Physical Medicine, Medical University of Lodz

• Robert Irzmański, profesor · Department of Internal Medicine and Cardiac Rehabilitation

• Katarzyna Glibov, doctor · Department of Internal Medicine and Cardiac Rehabilitation

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

CROSSOVER

Eligibility

Min Age

39 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-01-01

Primary Completion

2024-01-01

Completion

2025-01-01

Countries

• Poland

Study Locations